Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Jerome Goldschmidt, MD, Ralph V. Boccia, MD, Vivian J.M. Cline, Mariana Sacchi, MD, Andres Forero-Torres, Robert B. Sims, MD, Jingmin Liu, Jonathan W. Friedberg, MD MSSc

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136583

Published: 2020

Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Armando Santoro, Alison J. Moskowitz, MD, Silvia Ferrari, MD, Carmelo Carlo-Stella, MD, Michelle A. Fanale, MD, Stephen Francis, Mariana Sacchi, MD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137653

Published: 2020

Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 238.

https://doi.org/10.1182/blood-2019-122576

Published: 2019

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab

Daniel E. Zak, PhD, Carol Anne Anne Ogden, PhD, Alex F. Herrera, MD, Mariana Sacchi, MD, Matt Onsum, PhD

Blood (2018) 132 (Supplement 1): 2837.

https://doi.org/10.1182/blood-2018-99-115481

Published: 2018

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Jonathon B. Cohen, MDMS, John Kuruvilla, MD, Andreas Engert, MD, Stephen M. Ansell, MD PhD, Anas Younes, MD, Hun Ju Lee, MD, Marek Trněný, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham P. Collins, MB BS DPhil, Pier Luigi Zinzani, MD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M. Timmerman, MD, Mariana Sacchi, MD, Oumar Sy, PhD, Philippe Armand, MD PhD

Blood (2018) 132 (Supplement 1): 2932.

https://doi.org/10.1182/blood-2018-99-114502

Published: 2018

Journal Articles

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Philippe Armand, MD PhD, Andreas Engert, MD, Anas Younes, MD, Hun Ju Lee, MD, Armando Santoro, MD, Pier Luigi Zinzani, MD, John M. Timmerman, MD, Graham P. Collins, MB BS DPhil, Radhakrishnan Ramchandren, MD, Jonathon B. Cohen, MD MS, Jan Paul De Boer, MD PhD, Kerry J Savage, BSc, MD MSc, John Kuruvilla, MD, Marek Trněný, Margaret A. Shipp, MD, Mariana Sacchi, MD, Anne Sumbul, MS, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2018-99-112067

Published: 2018

Journal Articles

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Ranjana H. Advani, MD, Alison J. Moskowitz, MD, Nancy L. Bartlett, MD, Julie M. Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MSc, Beth A. Christian, MD, Stephen M. Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Carol Anne Ogden, PhD, David Taft, Daniel E. Zak, PhD, Mariana Sacchi, MD, Faith Galderisi, DO, Alex F. Herrera, MD

Blood (2018) 132 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2018-99-110002

Published: 2018

NARROW

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only